药物基因定型与慢性疼痛管理中患者报告结果的关联
Anna Bollinger1,2, Kurt E Hersberger1, Julia Gianora2
1Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Health services insights
|July 14, 2025
概括
药物遗传学 (PGx) 测试显著改善了慢性疼痛患者的与健康有关的生活质量,并减少了疼痛强度. 与非指导方法相比,PGx引导治疗显示出更好的结果.
科学领域:
- 药物基因组学 药物基因组学
- 疼痛管理 疼痛管理
- 临床结果 临床结果
背景情况:
- 慢性疼痛会对患者的健康相关生活质量 (HRQoL) 产生负面影响.
- 药物遗传学 (PGx) 测试通过优化药物治疗提供了个性化的疼痛管理.
- 对于PGx测试对患者报告结果 (PROs) 的影响尚不清楚.
研究的目的:
- 评估慢性疼痛患者的PGx测试和PRO之间的关联.
- 为了比较PGx引导治疗和非PGx引导治疗组之间的结果.
- 评估PGx测试后HRQoL和疼痛强度的变化.
主要方法:
- 观察案例系列与29名慢性疼痛患者的前后分析.
- 评估了PRO,包括HRQoL (EQ-5D-5L) 和疼痛强度 (数值评分表).
- 统计分析包括威尔科克森签名等级测试和效果大小计算,应用最小重要差异 (MID) 值.
主要成果:
- 平均EQ指数得分在PGx测试后显著改善 (P < .001,d = -0.84).
- 与非导向组相比,PGx引导治疗组在HRQoL和疼痛强度上显示出明显更大的改善 (P < .01).
- 大多数获得HRQoL和疼痛强度MID的患者接受了PGx引导治疗.
结论:
- 在慢性疼痛患者中,PGx测试显著改善HRQoL并降低疼痛强度.
- PGx引导治疗似乎产生了临床相关的改善.
- 需要进一步的受控研究来确认临床影响和经济可行性.
相关概念视频
Analysis of Population Pharmacokinetic Data
390
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
390
Analgesia and Pain Management
811
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
811
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
116
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
116
Pharmacodynamics: Overview and Principles
2.1K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.1K
Pharmacovigilance
996
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996


